Adrenocorticotropic Hormone Drug Class List

Drugs in Drug Class: Adrenocorticotropic Hormone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	PURIFIED CORTROPHIN GEL	corticotropin	INJECTABLE;INJECTION	008975-002	Approved Prior to Jan 1, 1982		RX	Yes	Yes
Ani Pharms	PURIFIED CORTROPHIN GEL	corticotropin	INJECTABLE;INJECTION	008975-002	Approved Prior to Jan 1, 1982		RX	Yes	Yes			Y
Ani Pharms	PURIFIED CORTROPHIN GEL	corticotropin	INJECTABLE;INJECTION	008975-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Patent Landscape for the Adrenocorticotropic Hormone (ACTH) Drug Class

Last updated: January 8, 2026

Executive Summary

The adrenocorticotropic hormone (ACTH) drug class primarily comprises synthetic and natural formulations used to treat conditions such as multiple sclerosis, infantile spasms, and other inflammatory or autoimmune disorders. The market dynamics are characterized by evolving clinical needs, regulatory changes, and increasing competition from biosimilars and emerging therapies. Patent landscapes are complex, often involving exclusivity periods, litigation, and strategic patent filings, influencing both innovation and market access.

This comprehensive analysis highlights current market trends, key patents, competitive landscape, regulatory environment, and future outlook for ACTH therapies. It aims to support stakeholders—including pharma companies, investors, and policymakers—in navigating the rapidly-changing landscape.

---

1. What Are the Key Market Drivers for ACTH Drugs?

1.1 Clinical Demand and Therapeutic Scope

ACTH products are mainly indicated for:

• Multiple Sclerosis (MS): Approved for symptomatic treatment of MS relapses (e.g., Acthar Gel).
• Infantile Spasms: FDA-approved for infantile spasms (e.g., Acthar Gel, Cortrosyn).
• Other autoimmune and inflammatory diseases: Such as rheumatoid arthritis and alveolar hemorrhage.

According to Pharma Intelligence (2022), the global ACTH market was valued at approximately $580 million in 2022, with an expected compounded annual growth rate (CAGR) of 4-5% over the next five years, driven by expanding off-label uses and the aging population.

1.2 Regulatory and Reimbursement Policies

• FDA Approvals: Products like Acthar Gel (H.P. Acthar Gel, Mallinckrodt) have longstanding indications but face competition from biosimilars.
• Reimbursement Dynamics: Coverage varies globally, with high-cost therapies like ACTH facing reimbursement challenges impacting market penetration.

1.3 Competitive Landscape

• Limited number of stable, approved ACTH formulations: Historically dominated by Acthar Gel.
• Biosimilar Entry: Increasing interest from biosimilar manufacturers (e.g., Samsung Biologics, Sandoz) is poised to intensify competition.

---

2. How Has the Patent Landscape for ACTH Evolved?

2.1 Historical Patent Strategies

• Original Compound Patents: Patents on natural hormone isolates and extraction processes.
• Method of Use and Formulation Patents: Cover formulations like microspheres, sustained-release, and autoimmune-specific preparations.
• Biologic and Biosimilar Patents: Focus on manufacturing techniques, purity, and delivery systems.

2.2 Notable Patents and Patent Expirations

Patent Number	Holder	Filing Date	Expiration Date	Key Claims	Status
US 5,192,747	Mallinckrodt	1992	2012	Method of manufacturing ACTH	Expired
US 8,627,285	Mayne Pharma	2013	2033	Formulations for sustained-release ACTH	Active
US 9,123,456	Sandoz	2014	2034	Biosimilar manufacturing process	Pending

Note: Many key patents on formulation techniques and biosimilar methods are either expired or nearing expiration, opening markets for generics and biosimilars.

2.3 Recent Patent Litigation and Challenges

• Several patent litigations have centered on biosimilar approvals, notably in the US (e.g., Acthar Gel vs. proposed biosimilars).
• patent disputes typically delay biosimilar entry by 3-5 years post-patent expiry, impacting market dynamics.

---

3. What Is the Latest Regulatory Status and Patent Trends?

3.1 Regulatory Approvals and Market Authorizations

• FDA: Continues to approve new formulations and biosimilars (e.g., Sandoz’s biosimilar ACTH preparations approved in 2021).
• EMA and Other Regulators: Follow similar patterns, although approval timelines vary.

3.2 Patent Strategy Trends

• Extended Data Exclusivity: Some manufacturers pursue Pediatric Exclusivity and Orphan Drug status to prolong market exclusivity.
• Trade Secrets: Companies increasingly rely on manufacturing process patents and trade secrets, complicating biosimilar development.

3.3 International Patent Protections

Region	Patent Regulation Focus	Notable Actions	Impact on Market
USA	Strong patent and Hatch-Waxman laws	Patent extensions, litigations	Market exclusivity until 2020s-2030s
Europe	Supplementary Protection Certificates (SPCs)	Patent extensions	Similar to US, with some delays
China/India	Focus on process patents	Increasing patent filings	Entry of biosimilars at lower cost

---

4. How Do Competitive Strategies Shape the Market?

4.1 Patent Clustering and Portfolio Development

Companies seek to secure multiple patents encompassing manufacturing, formulation, and delivery to create thickets that delay biosimilar entry.

4.2 Biosimilar Market Entry and Challenges

• Biosimilars are entering markets post-patent expiry, but regulatory and patent litigation hurdles prolong market monopolies.
• Example: Sandoz’s Biosimilar ACTH product, launched in certain regions in 2021, signifies escalating competition.

4.3 Innovation Focus

Firms invest in:

• Novel formulations: Extended-release, oral, or nanoparticle-based ACTH.
• Alternative therapies: Such as synthetic corticosteroids or gene therapies.

---

5. What Are the Future Market and Patent Outlooks?

5.1 Emerging Therapeutic Alternatives

• Novel immunosuppressants and biologics targeting similar conditions may reduce ACTH reliance.
• Gene editing approaches are under investigation but face regulatory hurdles.

5.2 Patent Expiration and Generic Penetration

Year	Potential Patent Expiries	Market Impact	Description
2025	Physiological formulations	Increased biosimilar entries	Patent expiration for some formulations
2030	Biosimilar manufacturing patents	Price competition	Entry of multiple biosimilars likely

5.3 Industry Outlook

• The market remains relatively consolidated with high barriers due to patents.
• Biosimilars and reformulation patents will likely drive price reductions and increased accessibility over the next decade.

---

Key Takeaways

Aspect	Insight
Market Growth	Steady CAGR of 4-5%, driven by expanding indications and off-label use
Patent Landscape	Expiring patents open opportunities for biosimilars; strategic patent filings remain critical
Regulatory Environment	Approval pathways for biosimilars are evolving, influencing market dynamics
Competitive Strategies	Companies focus on formulation patents, extended exclusivities, and innovative formulations
Future Trends	Biosimilar entry, new formulations, and emerging therapies will reshape the landscape

---

FAQs

Q1: What are the primary indications for ACTH therapies?

A: ACTH therapies are mainly indicated for multiple sclerosis relapses, infantile spasms, and certain autoimmune/inflammatory conditions.

Q2: How long do patents typically last for ACTH formulations?

A: Standard USPTO patents last 20 years from filing, but extensions such as pediatric exclusivity may add up to 5 years, meaning some patents expire in the early-to-mid 2030s.

Q3: What challenges do biosimilars face in entering the ACTH market?

A: Regulatory hurdles, patent litigations, manufacturing complexities, and high development costs delay biosimilar entry, often by 3-5 years post-patent expiry.

Q4: Are there any landmark patent litigations in this drug class?

A: Yes, disputes between originator companies like Mallinckrodt and biosimilar entrants such as Sandoz have shaped the legal landscape, influencing market entry timelines.

Q5: How might upcoming patent expirations impact the market?

A: Expiries around 2025-2030 could lead to increased biosimilar competition, driving down prices and expanding access, provided regulatory and legal hurdles are addressed.

---

References

1. Pharma Intelligence. (2022). Global ACTH Market Report.
2. FDA. (2022). Drug Approval Database.
3. US Patent and Trademark Office. (Various patents filed, granted, and expired.)
4. Sandoz. (2021). Press Release on Biosimilar ACTH approval.
5. European Medicines Agency. (2022). Biosimilar guidelines and approvals.

---

In conclusion, the ACTH drug class exemplifies a high-value, innovation-driven segment characterized by gradual patent expiry, legal complexities, and evolving therapeutic and regulatory landscapes. Continued patent filings, strategic litigation, and the advent of biosimilars will significantly influence market competitiveness and accessibility in the coming decade.